Human Genome Sciences, Inc.

Pablo Jimenez

Donna Mendrick

Steven M Ruben

Reiner L Gentz

Mark A Rampy

Jian Ni

Paul A Moore

Patrick J Dillon

Timothy A Coleman

D Roxanne Duan

Joachim R Gruber

Craig A Rosen

Mark D Adams

Haodong Li

Brent L Kreider

Vikram P Patel

Michael Antonaccio

Arthur Louie

Deborah Russell

There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &#x3b2;8 (CK&#x3b2;8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&#x3b3; and chemokine &#x3b2;1 (CK&#x3b2;1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.

Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides

There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &#x3b2;8 (CK&#x3b2;8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&#x3b3; and chemokine &#x3b2;1(CK&#x3b2;1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.

Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as 'KGF-2' also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

Keratinocyte growth factor-2 polynucleotides

Antibodies to monocyte-colony inhibitory factor (M-CIF)

Keratinocyte growth factor-2

There are disclosed therapeutic compositions and methods using a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&ggr; chemokine &bgr;1(CK&bgr;1 or ckb-1)), as well as ioslated nucleic acid molecules encoding M-CIF, and vectors, host cells and recombinant methods for producing the same.

Human monocyte colony inhibitory factor (M-CIF) polypeptides

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as &ldquo;KGF-2&rdquo; also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

The present invention relates to the administration of Keratinocyte Growth Factor-2 (KGF-2) to stimulate proliferation of platelets and to increase levels of fibrinogen, albumin, globulin and total serum protein. Further, the present invention relates to administering KGF-2 to protect or treat the bladder and prostate. Moreover, the present invention relates to administering KGF-2 to stimulate growth of nasal, oral, and esophageal mucosa, lacrimal glands, salivary glands and Goblet cells.

Therapeutic uses of keratinocyte growth factor-2

Growing community of inventors

Chatham, NJ, United States of America

Pablo Jimenez